Clinical Trials Logo

Carcinoid Syndrome clinical trials

View clinical trials related to Carcinoid Syndrome.

Filter by:

NCT ID: NCT01018953 Terminated - Carcinoid Syndrome Clinical Trials

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

CAMPANULA
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.

NCT ID: NCT00884715 Terminated - Carcinoid Syndrome Clinical Trials

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

NCT ID: NCT00853047 Completed - Carcinoid Syndrome Clinical Trials

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.

NCT ID: NCT00774930 Completed - Carcinoid Syndrome Clinical Trials

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

ELECT
Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.